Inspira Technologies Oxy BHN ( (IINN) ) has provided an update.
Inspira Technologies announced its full-year 2024 financial results, highlighting significant technological advancements and regulatory milestones. The company achieved FDA clearance for its INSPIRA ART100 system, which has been deployed for evaluation in U.S. hospitals. Inspira also reported advancements in its HYLA blood sensor and VORTX technology, alongside strategic partnerships to enhance production capabilities. Financially, the company reduced operating expenses and maintained a strong cash position, supporting ongoing product development and regulatory submissions.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a company focused on developing innovative respiratory support and diagnostic technologies. Their flagship product, the INSPIRA ART system, is designed to revolutionize critical care by allowing patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The company also offers the FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass procedures and is developing the HYLA blood sensor for real-time blood monitoring.
YTD Price Performance: -25.71%
Average Trading Volume: 1,248,131
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.93M
For detailed information about IINN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com